A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations
Criteria:Be ≥ 40 years of age and capable of giving signed informed consent.
Have documented diagnosis of COPD for at least one year prior to enrolment.
Have documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months prior to enrolment.
Have documented optimised inhaled dual or triple therapy for at least 3 months prior to enrolment.
Have smoking history of ≥ 10 pack-years.